ULTRAVIST (PHARMACY BULK)
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ULTRAVIST (Pharmacy Bulk) is an injectable small-molecule contrast agent approved by the FDA in 2002. The product is indicated for diagnostic imaging procedures requiring intravenous contrast administration. Mechanism of action involves iodine-based radiographic contrast to enhance visualization in medical imaging.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), suggesting team focus on generic transition planning and operational efficiency.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ULTRAVIST offers exposure to mature product lifecycle management and generic transition strategy within a major pharmaceutical company. Career opportunities lean toward operational efficiency, payer relations, and institutional sales rather than innovative drug development.
Brand ManagerMedical Science Liaison
Worked on ULTRAVIST (PHARMACY BULK) at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.